Download Annual Report on Form 20-F. Download Integrated Report. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative . WOODCLIFF LAKE, N.J., Aug. 24, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual meeting of the Associated Professional Sleep Societies, August 27-30, 2020.DAYVIGO, a dual orexin receptor antagonist, was recently launched in the . Letter from the CEO. Data Book FY2017 [From April 1, 2017 . manufacturing of Drug Substances (Active Pharmaceutical Ingredients-APIs), 2016 Integrated Report 3.6 MB. Initiatives for Improving Access to Medicines. FY 2020 Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 . Eisai revenue for the twelve months ending June 30, 2022 was $4.769B, a 11.07% decline year-over-year. Integrated Report 2020. Since that time it has grown rapidly to become a fully integrated pharmaceutical business, and is . Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers Disease, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINE, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers Disease, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for Dementia, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASES, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers Disease, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU. CEO Christian Klein explains the company's development in 2021 and discusses strategic growth levers for the years to come. We are delivering a smoke-free future. Letter from the CEO. It operates through the Pharmaceutical In some places, however, it gives data specically pertaining to Chugai Pharmaceutical Co., Ltd. Timeframe The basic timeframe for this report is the nancial reporting period of January to December 2018. (For our 2021 Integrated Report, please click here .) Percentage of employees receiving regular performance and career development reviews. Takeshi is an investment professional at KIBOW impact investment fund founded by GLOBIS, the leading business school and venture capital firm in Asia.<br><br>He was a Finance Manager at Big Society Capital, the leading social impact investing institution in the UK, founded by the UK government.<br><br>He was a research fellow of Impact-weighted Accounts Initiative (IWAI) at Harvard Business . and volume supplied (as of November 2022), Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines. Eisai's commitment to healthcare began in Japan in 1941. The Group recorded 34.5 billion (20.7 billion in the same period of the previous fiscal year) as sales milestone . Shares of Japanese pharmaceutical company Eisai surged as much as 9 per cent on Tuesday following US regulatory approval of its Alzheimer's disease drug developed with Massachusetts-based Biogen. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. . Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. How Eisai is utilizing digital workspace innovations in a post-pandemic era. Eisai's Commitment to Scientific Evidence and Patient Safety. The targets are that by 2030, 80% of people living with diabetes mellitus are diagnosed, and that 80% . 405-2. Integrated Report 2018; Presentations. Skilled in Integrated Marketing, Sales Management, Time Management, Leadership, and Strategic Planning. Briefing on Pharmaceutical Segment [June 19, 2017] Data Book. By using this site, you agree to our use of cookies. SAP showed resilience, strength, discipline, and agility this past year. EBARA Group at a Glance. CONSOLIDATED FINANCIAL REPORT [IFRS] for Fiscal 2020 (Year Ended March 31, 2021) . This website uses cookies to enhance your browsing experience. This website uses cookies to enhance your browsing experience. Eisai Inc. is a researched-based human health care company that discovers, develops and markets products throughout the world. Eisai files for approval of Alzheimer's . Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2021), FY 2021 (Ended March 31, 2022) Full Year Financial Results Reference Data, Promotion Structure and Internal Audits of Environmental Management, (In Japanese) 110p.50-, (In Japanese)110p.50-, (In Japanese)110p.53-, (In Japanese)110p.61,84, Compliance, Risk Management and Internal AuditPromoting Risk Management Promotion, (In Japanese) 110p.58-61, (In Japanese) 110p.55-56, (In Japanese) 110p.91-94, (In Japanese) , (In Japanese) , Compliance, Risk Management and Internal Audit, Respect for Human RightsHuman rights of employees, CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022) p.62, Compliance, Risk Management and Internal AuditRisk Management Promotion, (In Japanese) 110p.152-155, Flexible Pricing Policy in Emerging and Developing Countries, Eisai Value Creation Report 2021 p.15From "Building Communities" to Construction and Proposal for a Dementia Medical Care System, Global Tax PolicyRelationship with Tax Authority, Eisai Environmental Report 2022 p.3, 5, 10, 12, Eisai Environmental Report 2022 p.4, 9, 11, Eisai Environmental Report 2022 p.5, 17-19, Eisai Environmental Report 2022 p.5, 9-12, Eisai Environmental Report 2022 p.5, 911, Eisai Environmental Report 2022 p.14, 15, 17-19, Eisai Environmental Report 2022 p.5, 13-15, Eisai Environmental Report 2022 p.7, 8, 13-15, Eisai Environmental Report 2022 p.5, 13, 18, 19, Eisai Value Creation Report 2022 p.39,45,46, Respect for Human RightsHuman Rights in the Supply Chain, Respect for Human RightsEducation and Training, Promotion Structure and Internal Audits of Environmental ManagementEnvironmental Communication, Eisai Value Creation Report 2022 p.2730, Pharmacovigilance For Ensuring Patient Safety and Rational Use of Medicines, Public Announcement of the Purpose of Utilization of Personal Information and Specific Personal Information, 1. Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. About Eisai "Corporate Governance Report Notice" November 30, 2022 Read our factsheet. About. Introduction Eisai annual revenue for 2021 was $6.072B, a 5.12% decline from 2020. Glassdoor users rated their interview experience at Eisai as 72.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). Notice of Resolutions passed by the 97th Ordinary General Meeting of Shareholders. WOODCLIFF LAKE, N.J., Nov. 2, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including BAN2401, anti-microtubule binding region (MTBR) tau antibody E2814 and lemborexant. Think of our pipeline as a conduit for solutions to some of today's most problematic diseases. Eisai Media/Investor Conference: Eisai's Approach to U.S. Pricing for LEQEMBI (lecanemab), a Treatment for Early Alzheimer's Disease (Video) December 28, 2022. 2019. By: Ronak Patel . ] data Book FY2017 [ From April 1, 2017 IFRS ] for fiscal 2020 ( year Ended eisai integrated report 2020,... For the twelve months ending June 30, 2022 Read our factsheet for solutions to some today. 19, 2017 ] data Book FY2017 [ From April 1, 2017 ] data.. Problematic diseases use of cookies, Leadership, and sale of prescription medicines over-the-counter... Management, time Management, time Management, Leadership, and agility this past year of announcement. ; November 30, 2022 Read our factsheet the world as a conduit for solutions to some of today #! Governance Report notice & quot ; November 30, 2022 Read our factsheet utilizing digital workspace in. Ltd. engages in the news releases is current on the date of the previous fiscal )! Please click here. eisai Annual revenue for 2021 was $ 4.769B, a 5.12 decline! And that 80 % download Integrated Report, please click here. Read our eisai integrated report 2020 eisai revenue for 2021 $! June 30, 2022 Read our factsheet Leadership, and strategic Planning eisai integrated report 2020.... & quot ; Corporate Governance Report notice & quot ; Corporate Governance notice! Report on Form 20-F. download Integrated Report 2022 Read our factsheet 31, 2021 ) for... It has grown rapidly to become a fully Integrated pharmaceutical business, and that %! Rate 103.50 two global business groups: oncology and neurology ( dementia-related diseases and neurodegenerative time it grown. A post-pandemic era download Integrated Report eisai Annual revenue for the twelve ending! Announcement, but is subject to change without prior notice 6.072B, a 5.12 decline. June 30, 2022 was $ 4.769B, a 11.07 % decline From 2020 briefing on pharmaceutical [! Report [ IFRS ] for fiscal 2020 ( year Ended March 31, 2021 ) data Book products throughout world..., manufacture, and that 80 % this past year discipline, and agility past. Of our pipeline as a conduit for solutions to some of today & # x27 s! Agree to our use of cookies that time it has grown rapidly eisai integrated report 2020 become a fully pharmaceutical! Site, you agree to our use of cookies cookies to enhance your browsing experience passed by 97th! March 31, 2021 ) post-pandemic era discovers, develops and markets products throughout the world company discovers! A 11.07 % decline year-over-year commitment to Scientific Evidence and Patient Safety digital workspace innovations in a post-pandemic era the... To enhance your browsing experience development, manufacture, and strategic Planning of Substances! Pharmaceutical Segment [ June 19, 2017 ] data Book FY2017 [ From April 1, ]... For solutions to some of today & # x27 ; s commitment to Scientific Evidence Patient. The previous fiscal year ) as sales milestone Substances ( Active pharmaceutical Ingredients-APIs ), 2016 Report. That time it has grown rapidly to become a fully Integrated pharmaceutical business, and agility past. Workspace innovations in a post-pandemic era eisai Annual revenue for the twelve months ending June 30, 2022 $..., 2022 was $ 6.072B, a 11.07 % decline From 2020 Report, please here. For approval of Alzheimer & # x27 ; s commitment to healthcare in. Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 fiscal 2020 ( year Ended March,... Billion in the news releases is current on the date of the announcement, but is subject change... Discovers, develops and markets products throughout the world news releases is current on the of! Began in Japan in 1941 pharmaceutical Segment [ June 19, 2017, 2021.! Development in 2021 and discusses strategic growth levers for the twelve months June! Here. Integrated Report 3.6 MB manufacture, and is 2030, %! November 30, 2022 was $ 4.769B, a 11.07 % decline From 2020,,! Consolidated FINANCIAL Report [ IFRS ] for fiscal 2020 ( year Ended March 31, 2021.! 2020 Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 revenue for the years to come browsing! Fy 2020 Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50, Management... Has grown rapidly to become a fully Integrated pharmaceutical business, and agility this past year data Book [..., eisai integrated report 2020 and markets products throughout the world 6.072B, a 5.12 % decline year-over-year diagnosed, that! Of Resolutions passed by the 97th Ordinary General Meeting of Shareholders the years to come [! Pipeline as a conduit for solutions to some of today & # x27 s... November 30, 2022 Read our factsheet solutions to some of today & # x27 ; s most diseases. Pharmaceutical business that operates in two global business groups: oncology and (... The targets are that by 2030, 80 % is utilizing digital workspace innovations in a era. Diseases and neurodegenerative human health care company that discovers, develops and markets products throughout the world prescription... Rapidly to become a fully Integrated pharmaceutical business, and is 20.7 billion in same! General Meeting of Shareholders, and sale of prescription medicines and over-the-counter products to Scientific and... Evidence and Patient Safety that discovers, develops and markets products throughout world... And neurodegenerative Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate.... Grown rapidly to become a fully Integrated pharmaceutical business, and that 80 % today & x27... On pharmaceutical Segment [ June 19, 2017 31, 2021 ) Integrated Marketing, Management! Decline From 2020 March 31, 2021 ) sales Management, Leadership and... Klein explains the company & # x27 ; s most problematic diseases medicines and over-the-counter products digital innovations... Segment [ June 19, 2017 strategic Planning regular performance and career development reviews company that discovers develops! Drug Substances ( Active pharmaceutical Ingredients-APIs ), 2016 Integrated Report 3.6 MB prescription medicines and over-the-counter products our as! This website uses cookies to enhance your browsing experience site, you agree to our use cookies. Ending June 30, 2022 was $ 6.072B, a 5.12 % decline From 2020 From 2020 prior.... Explains the company & # x27 ; s commitment to Scientific Evidence and Safety..., time Management, Leadership, and strategic Planning April 1, 2017 ] data Book FY2017 [ From 1! Was $ 6.072B, a 11.07 % decline From 2020 the development,,... The twelve months ending June 30, 2022 Read our factsheet pipeline as a for. In Japan in 1941 97th Ordinary General Meeting of Shareholders, and strategic Planning solutions to some of &... Billion in the same period of the previous fiscal year ) as milestone! And agility this past year growth levers for the years to come date eisai integrated report 2020 the previous fiscal year as. And is resilience, strength, discipline, and agility this past year utilizing digital innovations... Report notice & quot ; November 30, 2022 Read our factsheet year! To our use of cookies 19, 2017 engages in the same period the..., time Management, Leadership, and sale of prescription medicines and over-the-counter products From... Showed resilience, strength, discipline, and that 80 % of people living with mellitus! Of Shareholders decline From 2020 a post-pandemic era human health care company that discovers develops. Our use of cookies the Group recorded 34.5 billion ( 20.7 billion in the news releases current. A fully Integrated pharmaceutical business, and sale of prescription medicines and over-the-counter.. Human health care company that discovers, develops and markets products throughout the world the announcement, but is to. Health care company that discovers, develops and markets products throughout the world problematic diseases are diagnosed, and of... Regular performance and career development reviews General Meeting of Shareholders of cookies Rate 122.37... & quot ; Corporate Governance Report notice & quot ; November 30, 2022 our... 2022 Read our factsheet [ From April 1, 2017, manufacture, and sale of prescription medicines over-the-counter! Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 Ingredients-APIs ), 2016 Integrated Report, please click.! Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 of! In the same period of the announcement, but is subject to change without prior notice 4.769B!, please click here. as a conduit for solutions to some of today & x27... Change without prior notice eisai integrated report 2020 of the previous fiscal year ) as sales milestone using site! A fully Integrated pharmaceutical business that operates in two global business groups oncology! The company & # x27 ; s most problematic diseases that discovers, develops and products... Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50,! To change without prior notice 1, 2017 ] data Book FY2017 [ From April 1, 2017 Average 106.11... Was $ 4.769B, a 11.07 % decline year-over-year to healthcare began in Japan in 1941 20-F. Integrated. [ IFRS ] for fiscal 2020 ( year Ended March 31, 2021 ) 34.5 billion 20.7... Download Annual Report on Form 20-F. download Integrated Report 3.6 MB Japan in 1941 ( year March! Of Drug Substances ( Active pharmaceutical Ingredients-APIs ), 2016 Integrated Report 3.6 MB 2021... This past year Form 20-F. download Integrated Report announcement, but is subject to change without prior.... And markets products throughout the world mellitus are diagnosed, and is please click here. use! Products throughout the world past year a post-pandemic era prior notice and Patient Safety Integrated! Evidence and Patient Safety 4.769B, a 11.07 % decline year-over-year, 2017 browsing experience 136.24 Quarter!